期刊文献+

成人幕上脑胶质母细胞瘤患者临床预后因素研究 被引量:3

Clinical prognostic factors of adult supratentorial glioblastoma
原文传递
导出
摘要 目的探讨成人脑胶质母细胞瘤(GBM)患者的治疗效果和预后因素。方法回顾性分析2007年1月至2018年3月首都医科大学附属北京天坛医院神经外科肿瘤四病区收治的635例GBM患者的临床资料。其中男性386例,女性249例,年龄(48.7±11.8)岁(范围:18~75岁)。按就诊年份将患者分成3组,其中2007—2010年组174例,2011—2014年组237例,2015—2018年组224例。采用Kaplan-Meier法对不同治疗时期的GBM患者的生存期进行分析,组间比较采用Log-rank检验,多因素分析采用Cox风险回归模型。结果2007—2010年组、2011—2014年组、2015—2018年组患者的中位无进展生存期(PFS)和总体生存期(OS)分别为9.0个月(95%CI:7.5~10.5)、10.0个月(95%CI:8.8~11.2)、12.0个月(95%CI:10.7~13.3)和17.0个月(95%CI:13.2~20.8)、20.0个月(95%CI:16.9~23.1)、23.0个月(95%CI:17.5~28.5),随着年份推移,患者PFS和OS均提高,差异有统计学意义(χ^2=9.693,P=0.008和χ^2=8.616,P=0.013)。多因素分析结果显示:年龄、切除程度、放疗和肿瘤远隔播散为独立预后因素(P值均<0.05)。结论随着临床治疗方案不断更新,国内GBM患者治疗效果明显改善,年龄、切除程度、放疗和肿瘤远隔播散是影响患者生存期的独立预后因素。 Objective To analyze the treatment effect of patients with glioblastoma (GBM) and explore prognostic factors. Methods The clinical data of 635 patients diagnosed as GBM at Neurosurgical Oncology Department Ⅳ of Beijing Tiantan Hospital, Capital Medical University from January 2007 to March 2018 were retrospectively reviewed. There were 386 males and 249 females with an age of (48.7±11.8) years (range: 18-75 years). Patients were divided into three groups according to the time of admission: 2007-2010 group(n=174), 2011-2014 group (n=237) and 2015-2018 group (n=224). Kaplan-Meier plot was used to analyze the effects of different treatment periods, treatment schemes and clinical factors on the survival of patients with GBM. Cox proportion hazard regression analysis was used to identify independent prognostic factors. Results The median progression-free survival (PFS) and overall survival (OS) of patients in 2007-2010 group, 2011-2014 group, 2015-2018 group was 9.0 months (95% CI: 7.5-10.5), 10.0 months (95% CI: 8.8-11.2), 12.0 months (95% CI: 10.7-13.3) and 17.0 months (95% CI: 13.2-20.8), 20.0 months (95% CI: 16.9-23.1), 23.0 months(95% CI: 17.5-28.5), respectively. The PFS and OS of patients improved significantly over the years (χ^2=9.693, P=0.008 and χ^2=8.616, P=0.013). Multivariate survival analysis showed that age, extent of resection, radiotherapy and tumor distant dissemination were independent prognostic factors (all P<0.05). Conclusions With the continuous development of clinical treatment regimen, the therapeutic effect of Chinese GBM patients has improved remarkably. Age, extent of resection, radiotherapy and tumor distant dissemination are independent prognostic factors associated with survival time.
作者 蒋海辉 任晓辉 崔勇 李铭孝 杨凯元 雷逸斐 林松 Jiang Haihui;Ren Xiaohui;Cui Yong;Li Mingxiao;Yang Kaiyuan;Lei Yifei;Lin Song(Department of Neurosurgery,Beijing Tiantan Hospital,Capital Medical University,Beijing 100070,China;Department of Neurosurgery,the Affiliated Hospital of Qingdao University,Qingdao 266071,China)
出处 《中华外科杂志》 CAS CSCD 北大核心 2019年第5期377-382,共6页 Chinese Journal of Surgery
基金 国家自然科学基金(81771309).
关键词 胶质母细胞瘤 治疗结果 预后 远隔播散 Glioblastoma Treatment outcome Prognosis Distant dissemination
  • 相关文献

参考文献2

二级参考文献36

  • 1Kotliarova S, Fine HA. SnapShot: Glioblastoma multiforme. Cancer Cell 2012;21:710-710.el.
  • 2Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008;359:492-507.
  • 3Welch M, Lai R. Glioblastoma multiforme. Curr Treat Options Neuro12009; 11:297-305.
  • 4Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn M J, et aL Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
  • 5Stupp R, Hegi ME, Mason WP, van den Bent M J, Taphoorn M J, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Onco12009;10:459-66.
  • 6Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: A randomized phase III clinical trial. J Clin Onco12013;31:4085-91.
  • 7DeAngelis LM. Brain tumors. N Engl J Med 2001;344:114-23.
  • 8Pirzkall A, McGue C, Saraswathy S, Cha S, Liu R, Vandenberg S, et al. Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma. Neuro Oncol 2009; 11:842-52.
  • 9Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80.
  • 10Laperriere N, Zuraw L, Cairncross G; Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site Group. Radiotherapy for newly diagnosed malignant glioma in adults: A systematic review. Radiother Onco12002;64:259-73..

共引文献29

同被引文献31

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部